Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
| Revenue (Most Recent Fiscal Year) | $15.45M |
| Net Income (Most Recent Fiscal Year) | $-111.57M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 26.43 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 38.24 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.27 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -229.67% |
| Net Margin (Trailing 12 Months) | -229.67% |
| Return on Equity (Trailing 12 Months) | -106.36% |
| Return on Assets (Trailing 12 Months) | -49.16% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.51 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.51 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.48 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.40 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.09 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.96 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.63 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 204.94M |
| Free Float | 199.41M |
| Market Capitalization | $379.14M |
| Average Volume (Last 20 Days) | 2.50M |
| Beta (Past 60 Months) | 0.95 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 77.70% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |